77%的肺癌病人患有HER2突变, 使用一种新的药丸, zongertinib, 减缩肿瘤, 提供一种毒性较低的治疗方法。 A new pill, zongertinib, shrank tumors in 77% of lung cancer patients with HER2 mutations, offering a less toxic treatment option.

根据在欧洲医疗肿瘤学学会大会上进行的一项全球试验,一种新药物 -- -- zongertinib -- -- 在用HER2突变治疗肺癌方面表现出重大前景。 A new drug, zongertinib, is showing significant promise in treating lung cancer with HER2 mutations, according to a global trial presented at the European Society for Medical Oncology Congress. 在对74名未经治疗的病人进行的一项研究中,77%的人患有肿瘤萎缩,8%的人完全丧失了肿瘤,96%的人的疾病得到了控制。 In a study of 74 untreated patients, 77% experienced tumor shrinkage, 8% had complete tumor disappearance, and 96% had their disease controlled. 作为一种日常避孕药,有针对性的治疗为化疗提供了一种毒性较低的替代疗法,一名病人报告两年来副作用最小,生活质量得到改善。 Taken as a daily pill, the targeted therapy offers a less toxic alternative to chemotherapy, with one patient reporting minimal side effects and improved quality of life over two years. 研究人员将结果称为一项重大突破,并计划进行第三阶段试验,将zongertinib与标准治疗方法作比较。 Researchers called the results a major breakthrough, and a phase III trial comparing zongertinib to standard treatments is planned. 在英国,HER2突变导致肺癌病例的4%,每年有49,000多人被诊断。 HER2 mutations drive up to 4% of lung cancer cases in the UK, where over 49,000 people are diagnosed annually.